Loading
A phase 1/2 trial of BL-M02D1 in non-small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors is a phase 1/2 interventional study registered as NCT05949619 by Sichuan Baili Pharmaceutical Co., Ltd., with 14 participants enrolled, started 2023-09-04 and due to reach its primary completion in 2025-12. Interventions recorded: BL-M02D1.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/